Please assess the completion status of the following clinical trial:

Trial Title: High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed of congenital haemophilia A or B with inhibitors to factor VIII or IX, respectively~* A history of 3 or more joint bleeds during the last 12 months~Exclusion Criteria:~* Joint bleeding within 7 days prior to trial start~* Treatment for bleeds within the last 5 days prior to trial start~* Clinically relevant coagulation disorders other than congenital haemophilia A or B

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).